Leerink Partnrs Has Positive Outlook of XOMA Q2 Earnings

XOMA Co. (NASDAQ:XOMA - Free Report) - Investment analysts at Leerink Partnrs lifted their Q2 2025 earnings per share (EPS) estimates for XOMA in a research note issued on Thursday, May 15th. Leerink Partnrs analyst D. Risinger now forecasts that the biotechnology company will post earnings per share of ($0.07) for the quarter, up from their prior forecast of ($0.22). The consensus estimate for XOMA's current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA's Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.09 EPS, FY2025 earnings at $0.10 EPS, FY2027 earnings at $1.55 EPS, FY2028 earnings at $3.89 EPS and FY2029 earnings at $6.02 EPS.

Several other analysts also recently weighed in on XOMA. HC Wainwright reiterated a "buy" rating and set a $104.00 target price on shares of XOMA in a research report on Friday, March 28th. Benchmark began coverage on shares of XOMA in a report on Thursday, April 17th. They set a "buy" rating and a $35.00 price objective for the company. Finally, Wall Street Zen raised shares of XOMA from a "sell" rating to a "hold" rating in a research note on Friday, April 11th.

XOMA Trading Down 1.0%

NASDAQ XOMA traded down $0.26 during trading on Monday, hitting $24.85. The stock had a trading volume of 15,672 shares, compared to its average volume of 30,762. XOMA has a one year low of $18.35 and a one year high of $35.00. The stock has a market capitalization of $297.38 million, a price-to-earnings ratio of -7.14 and a beta of 0.89. The stock has a 50 day simple moving average of $22.52 and a 200 day simple moving average of $25.31. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

XOMA (NASDAQ:XOMA - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.32. The firm had revenue of $15.91 million during the quarter, compared to analyst estimates of $6.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%.

Insider Activity

In other news, CEO Owen Hughes sold 25,637 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $25.38, for a total transaction of $650,667.06. Following the transaction, the chief executive officer now directly owns 62,701 shares of the company's stock, valued at approximately $1,591,351.38. This represents a 29.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CIO Bradley Sitko bought 4,134 shares of XOMA stock in a transaction that occurred on Friday, March 21st. The shares were acquired at an average cost of $23.89 per share, for a total transaction of $98,761.26. Following the completion of the transaction, the executive now directly owns 10,484 shares in the company, valued at $250,462.76. This represents a 65.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 29,312 shares of company stock worth $735,061. 7.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in XOMA. Woodline Partners LP increased its holdings in shares of XOMA by 63.9% during the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company's stock valued at $4,107,000 after acquiring an additional 60,927 shares in the last quarter. Nuveen LLC acquired a new position in XOMA during the 1st quarter valued at approximately $286,000. CM Management LLC increased its stake in XOMA by 16.4% during the 1st quarter. CM Management LLC now owns 64,000 shares of the biotechnology company's stock valued at $1,276,000 after purchasing an additional 9,000 shares in the last quarter. JPMorgan Chase & Co. increased its stake in XOMA by 238.9% during the 4th quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company's stock valued at $318,000 after purchasing an additional 8,522 shares in the last quarter. Finally, Barclays PLC increased its stake in XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock valued at $298,000 after purchasing an additional 8,447 shares in the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.